slides · global inventory
Comparison Frame
Framework collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 6,294
Current window 4,951-4,980
Pages 210
Rows per page 30
Framework
4,951-4,980 of 6,294
12
The slide uses a combination of bar charts for preclinical data and a summary table for clinical outcomes to demonstrate the superiority of NXC-201.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Solution & Approach1 hit
15
The slide highlights a significant difference in neurotoxicity percentages (4% vs 23-28%) and CRS onset/duration metrics.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Solution & Approach1 hit
23
The slide uses a visual timeline/chart hybrid to compare CAR-T cell expansion, sBCMA reduction, and side effect durations (CRS and ICANS) across three products.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & Proof1 hit
24
The slide uses a table structure to contrast treatment landscapes and patient outcomes, with a bar chart at the bottom illustrating patient growth.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & Proof1 hit
28
Includes detailed source citations in the footer.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & ProofLoop · Why Now1 hit
33
The table highlights superior response rates (100% ORR, 70% CR) for NXC-201 compared to competitors.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & Proof1 hit
35
The chart compares NXC-201 against other therapies categorized by prior BCMA treatment status.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & Proof1 hit
46
Immix Biopharma | Investor Presentation Deck | 64 slidesImmix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
47
Immix Biopharma | Investor Presentation Deck | 64 slidesImmix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
51
Includes survival curves (Kaplan-Meier style), tumor imaging, and median survival metrics.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
53
The slide uses a scatter plot to map clinical trials and a table to detail standard-of-care metrics by line of therapy.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
59
The slide compares efficacy data for Humira, Stelara, and Entyvio against their respective placebo groups.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
05
The chart highlights Carvykti's superior growth curve in its first six quarters compared to the peer set.Legend Biotech | Investor Presentation Deck | 14 slides · Legend Biotech
Conference presentation Investor relations Beat · Market SizeLoop · Cost Of Inaction1 hit
06
Uses checkmarks and X marks to visually contrast strategic positioning.Lionsgate | SPAC Presentation Deck | 30 slides · Lionsgate
Conference presentation Investment bank Beat · ProblemLoop · Cost Of Inaction1 hit
09
The slide uses a comparison frame to demonstrate the consistency and profitability of two distinct business segments.Lionsgate | SPAC Presentation Deck | 30 slides · Lionsgate
Conference presentation Investment bank Loop · Cost Of Inaction1 hit
12
The table compares a standard of care (Cyramza), a regulatory benchmark, and the company's own drug candidate (THIO-101).MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
27
The slide uses market cap data to establish valuation benchmarks and cites recent M&A activity as a validation of the sector's value.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Competition1 hit
08
The slide uses a standard comparison table format to contrast a competitor (Resmetirom) with the company's own asset (DA-1241).NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · SolutionLoop · Pattern Hunter1 hit
18
The slide uses preclinical data to demonstrate efficacy superiority over a market-leading GLP-1 agonist.NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · Market SizeLoop · Golden Circle1 hit
05
The table compares NYCB's performance at two different dates (9/30/22 and 12/31/23) against a peer median as of 9/30/23.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations 1 hit
14
The table compares NYCB (as of Dec 31, 2023) against industry benchmarks (as of Sept 30, 2023).New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
17
The chart highlights a significant spike in charge-offs for the S&P index during the 2008-2012 period compared to NYCB.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
19
The slide highlights that NYCB remains well-capitalized despite ongoing goodwill impairment assessments.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
20
The slide highlights NYCB's relative capital position using two different metrics (Adjusted vs Reported).New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
09
The slide uses a structured table to highlight gaps in current treatment standards.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
14
The slide uses a matrix-like structure to compare drug generations against clinical outcomes.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations Loop · Mece Breakdown1 hit
28
The slide uses a matrix-like comparison to highlight the unique value proposition of NVL-520 compared to standard-of-care drugs.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
14
The slide uses a matrix-style comparison to highlight the superior/differentiated profile of the 4th generation inhibitor NVL-655.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Loop · Jobs To Be Done1 hit
29
The slide uses a matrix-like comparison to highlight the unique value proposition of NVL-520 compared to standard-of-care drugs.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
37
Uses a side-by-side comparison framework to contrast 2L+ (salvage) and 1L (front-line) market opportunities.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit